This Healthcare Stock’s Bad News Could Create a $10 Billion Opportunity for Competitors

view original post

Eli Lilly is a leader in the market for GLP-1 medicines. The company’s Zepbound, indicated for weight loss, is racking up billions in quarterly sales. Its only real competitor in weight management is …